A clinical reference, drawn from MuseCell Innovations®'s 120+ peer-reviewed studies, on how Authentic Dezawa MuseCells® differ from conventional mesenchymal stem cells across safety, mechanism, and delivery.
Distributed under license in the United Arab Emirates by BioCell Technologies™
PMID 40601066 IV target-organ biodistribution · See §04 vs Traditional MSCs for full comparison
Dezawa MuseCells® carry a naturally immune-privileged profile — allowing for allogeneic (donor-based) administration without triggering rejection or requiring immunosuppressive drugs.1
| Immune Marker | Mechanism |
|---|---|
| HLA-G+ | Inhibits natural killer (NK) cells and cytotoxic T-cells, mimicking immune tolerance seen during pregnancy. |
| IDO+ | Converts tryptophan into kynurenine, which inhibits T-cell activation and dampens immune response at inflammation sites. |
| HLA-DR− | Absence of this antigen prevents activation of helper T-cells, reducing the risk of adaptive immune targeting. |
|
1 immune privilege: PMID 36339573 Kuroda 2022 — Endogenous reparative pluripotent Muse cells with a unique immune privilege system · PMID 38560897 Minatoguchi 2024 — Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatment | |
Four safety attributes that distinguish Dezawa MuseCells® from conventional cell therapies — each backed by published evidence.
| Safety Attribute | Dezawa MuseCells® |
|---|---|
| Tumor formation | None observed in vivo + preclinical2 |
| HLA matching required | No3 |
| Immunosuppression | Not required in any human trial3 |
| Pluripotency method | Natural (no reprogramming)4 |
| Allogeneic immunogenicity | Broader MSC field: ~15% of MSC patients in DSA-measurement studies developed donor-specific antibodies.5 Muse cells: HLA-G+ immune privilege — no DSA correlation with safety outcomes. |
|
2 nontumorigenicity: PMID 29041955 PMID 33924240 PMID 38261036 PMID 20421459 PMID 24471964 3 HLA matching / no immunosuppression: PMID 33924240 4 natural pluripotent-like: PMID 21628574 PMID 36241699 5 broader-field MSC immunogenicity: PMC8269175 (PMID 34279481) Sanabria-de la Torre 2021 — Alloreactive Immune Response Associated to Human Mesenchymal Stromal Cells Treatment: A Systematic Review | |
Five characteristics that distinguish this cell line in published literature.
Pluripotent-like. Dezawa MuseCells® spontaneously differentiate into ectoderm, mesoderm, and endoderm lineages in vivo.
Non-tumorigenic. They do not form teratoma — even in long-term immunodeficient mouse models.
Stress-enduring. They survive harsh environments (hypoxia, serum deprivation) that other stem cells cannot.
Immune tolerance. HLA-G+, IDO+, HLA-DR− profile enables allogeneic use without immunosuppressants.
Stable karyotype. Dezawa MuseCells® maintain chromosomal integrity and low telomerase, minimizing mutation risk.
Backed by 120+ global publications — one of the strongest evidence bases in regenerative medicine.
Dezawa MuseCells® and Dezawa MuseExosomes® have been studied primarily in Japan and, in published research, have demonstrated advantages over traditional MSCs across pluripotency, stress resistance, and safety.
Naturally pluripotent-like. Stress-enduring. IV-delivered to target organs.
Multipotent. Limited differentiation. Local injection; lung-clearance on IV.
Tags: CLIN published clinical · PREP active or in preparation · PRE preclinical · EXP exploratory
Neurology
CNS · motor neuron · perinatal
Cardiovascular
AMI · cardiometabolic
Skin & Wound Healing
EB · cornea · scarring
Orthopedics
SCI · joint · cartilage
Renal
CKD · FSGS · glomerular
Hepatic
regeneration · fibrosis
Pulmonary
IR injury · ARDS
Aesthetics
facial · split-face · skin
Longevity & Healthspan
aging · frailty · performance
Autoimmune & Immune Privilege
mechanism · inflammation
Translational & Multi-indication
cross-border · multi-program
Future Research Directions
additional indications